[Prognostic value of the L-Dopa and clonidine GH stimulation tests in patients with endogenous growth hormone deficiency - retrospective analysis after discontinuation of treatment - own experience].

What Was Tested

This clinical trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Was to estimate a prognostic importance of the GH stimulation tests (L-Dopa and clonidine) in patients with severe (sGHD) and partial growth hormone deficiency (pGHD).

The results of growth hormone treatment (rhGH) were analyzed in the both groups.

Why It Was Studied

Assessment of growth hormone (GH) deficiency in short children is still limited with complicated and heterogeneous scheme of the diagnostic tests.

Who Took Part

The study group was 41 children.

By PubMed's age tags, the people studied were teenagers, both men and women.

The study group consists of 41 children, which used to be treated with rhGH.

How the Study Was Run

An insulin test was performed and according to the results two subgroups were distinguished: sGHD - n=11 and pGHD - n=30.

What Was Measured

Assessment of growth hormone (GH) deficiency in short children is still limited with complicated and heterogeneous scheme of the diagnostic tests.

The subject headings attached to it are Body Height, Growth Disorders, Growth Hormone, Human Growth Hormone, Levodopa and Prognosis.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 41 children.

The abstract goes on to report its results in about 10 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2009 (Pediatric endocrinology, diabetes, and metabolism), a journal based in Poland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.